Evidence map›Paper›PMID 29781814›Full record

ArticleThe Journal of clinical investigation2018

Lymphoid tissue fibrosis is associated with impaired vaccine responses.

Cissy Kityo, Krystelle Nganou Makamdop, Meghan Rothenberger, Jeffrey G Chipman, Torfi Hoskuldsson, Gregory J Beilman, Bartosz Grzywacz, Peter Mugyenyi, Francis Ssali, Rama S Akondy and 23 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. A Systematic Review on Yellow Fever Vaccine and Adverse Events.Global health, epidemiology and genomics · 2026
    Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Lethal COVID-19 associates with RAAS-induced inflammation for multiple organ damage including mediastinal lymph nodes.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Reduced immunogenicity of a liveFrontiers in immunology · 2023
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors at 8 institutions in 2 countries.

Cissy KityoJoint Clinical Research Center, Kampala, Uganda.
Krystelle Nganou MakamdopHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Meghan RothenbergerUniversity of Minnesota, Minneapolis, Minnesota, USA.
Jeffrey G ChipmanUniversity of Minnesota, Minneapolis, Minnesota, USA.
Torfi HoskuldssonUniversity of Minnesota, Minneapolis, Minnesota, USA.
Gregory J BeilmanUniversity of Minnesota, Minneapolis, Minnesota, USA.
Bartosz GrzywaczUniversity of Minnesota, Minneapolis, Minnesota, USA.
Peter MugyenyiJoint Clinical Research Center, Kampala, Uganda.
Francis SsaliJoint Clinical Research Center, Kampala, Uganda.
Rama S AkondyEmory Vaccine Center, and Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA.
Jodi AndersonUniversity of Minnesota, Minneapolis, Minnesota, USA.
Thomas E SchmidtUniversity of Minnesota, Minneapolis, Minnesota, USA.
Thomas ReimannUniversity of Minnesota, Minneapolis, Minnesota, USA.
Samuel P CallistoUniversity of Minnesota, Minneapolis, Minnesota, USA.
Jordan SchoephoersterUniversity of Minnesota, Minneapolis, Minnesota, USA.
Jared SchusterUniversity of Minnesota, Minneapolis, Minnesota, USA.
Proscovia MulomaJoint Clinical Research Center, Kampala, Uganda.
Patrick SsengendoJoint Clinical Research Center, Kampala, Uganda.
Eirini MoysiHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Constantinos PetrovasHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Ray LanciottiCenters for Disease Control, Atlanta, Georgia, USA.
Lin ZhangUniversity of Minnesota, Minneapolis, Minnesota, USA.
Maria T ArévaloCenter for Vaccines and Immunology and Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.
Benigno RodriguezCase Western Reserve University, Cleveland, Ohio, USA.
Ted M RossCenter for Vaccines and Immunology and Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.
Lydie TrautmannU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Rafick-Pierre SekalyCase Western Reserve University, Cleveland, Ohio, USA.
Michael M LedermanCase Western Reserve University, Cleveland, Ohio, USA.
Richard A KoupImmunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Rafi AhmedEmory Vaccine Center, and Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA.
Cavan ReillyUniversity of Minnesota, Minneapolis, Minnesota, USA.
Daniel C DouekHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Timothy W SchackerUniversity of Minnesota, Minneapolis, Minnesota, USA.
University of Minnesota · USJoint Clinical Research Centre · UGNational Institutes of Health · USCase Western Reserve University · USEmory University · USUniversity of Georgia · USCenters for Disease Control and Prevention · USHenry M. Jackson Foundation · US

Funding

WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
Tfh and B cells in HIV/SIV pathogenesis and vaccinationZIAAI005015 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$24.1M
Testing of Blood Samples for Immune Response and Vaccine ResearchZIAAI005073 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$23.4M
HIV/SIV Replication In VivoZIAAI005014 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$22.7M
The Genome Analysis CoreZICAI005133 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2019 to 2025
$16.9M
Virological Measurements of Cryptic ReplicationP01AI074340 · NIAID · UNIVERSITY OF MINNESOTA · PI SCHACKER, TIMOTHY W · 2008 to 2012
$12.1M
InflammationZIAAI005031 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2024
$5.9M
Antifibrotic Therapy to Improve Immune reconstitution in HIVR01AI093319 · NIAID · UNIVERSITY OF MINNESOTA · PI SCHACKER, TIMOTHY W · 2011 to 2014
$2.8M
NCATS NIH HHS UL1 TR000114NIAID NIH HHS P01 AI074340NIAID NIH HHS P30 AI036219NIAID NIH HHS R01 AI093319
6 · The paper itself

Abstract

Vaccine responses vary by geographic location. We have previously described how HIV-associated inflammation leads to fibrosis of secondary lymph nodes (LNs) and T cell depletion. We hypothesized that other infections may cause LN inflammation and fibrosis, in a process similar to that seen in HIV infection, which may lead to T cell depletion and affect vaccine responses. We studied LNs of individuals from Kampala, Uganda, before and after yellow fever vaccination (YFV) and found fibrosis in LNs that was similar to that seen in HIV infection. We found blunted antibody responses to YFV that correlated to the amount of LN fibrosis and loss of T cells, including T follicular helper cells. These data suggest that LN fibrosis is not limited to HIV infection and may be associated with impaired immunologic responses to vaccines. This may have an impact on vaccine development, especially for infectious diseases prevalent in the developing world.

Indexed as

VaccinationAdaptive ImmunityAdultAntibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesClonal AnergyCollagenCytokinesFemaleFibrosisHIV InfectionsHIV SeronegativityHumansImmune ToleranceLymphocyte ActivationAntibodies, NeutralizingAntibodies, ViralCollagenCytokinesYellow Fever VaccineAdaptive immunityBacterial vaccinesFibrosisImmunologyVaccines

Identifiers

PMID29781814
PMCPMC6025977
OpenAlexW2803143011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.